Last reviewed · How we verify

Cisplatin and Gemcitabine

Delcath Systems Inc. · Phase 2 active Small molecule

Cisplatin and Gemcitabine is a Platinum-based alkylating agent and nucleoside analog Small molecule drug developed by Delcath Systems Inc.. It is currently in Phase 2 development for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer. Also known as: Cis/Gem, Gemzar, Platinol.

Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks.

Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks. Used for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

At a glance

Generic nameCisplatin and Gemcitabine
Also known asCis/Gem, Gemzar, Platinol
SponsorDelcath Systems Inc.
Drug classPlatinum-based alkylating agent and nucleoside analog
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Cisplatin works by forming platinum-DNA adducts, which trigger apoptosis in cancer cells. Gemcitabine is metabolized into its active form, which is then incorporated into DNA, causing DNA strand breaks and inhibiting DNA synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cisplatin and Gemcitabine

What is Cisplatin and Gemcitabine?

Cisplatin and Gemcitabine is a Platinum-based alkylating agent and nucleoside analog drug developed by Delcath Systems Inc., indicated for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

How does Cisplatin and Gemcitabine work?

Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by causing DNA strand breaks.

What is Cisplatin and Gemcitabine used for?

Cisplatin and Gemcitabine is indicated for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.

Who makes Cisplatin and Gemcitabine?

Cisplatin and Gemcitabine is developed by Delcath Systems Inc. (see full Delcath Systems Inc. pipeline at /company/delcath-systems-inc).

Is Cisplatin and Gemcitabine also known as anything else?

Cisplatin and Gemcitabine is also known as Cis/Gem, Gemzar, Platinol.

What drug class is Cisplatin and Gemcitabine in?

Cisplatin and Gemcitabine belongs to the Platinum-based alkylating agent and nucleoside analog class. See all Platinum-based alkylating agent and nucleoside analog drugs at /class/platinum-based-alkylating-agent-and-nucleoside-analog.

What development phase is Cisplatin and Gemcitabine in?

Cisplatin and Gemcitabine is in Phase 2.

What are the side effects of Cisplatin and Gemcitabine?

Common side effects of Cisplatin and Gemcitabine include Neutropenia, Nausea and vomiting, Anemia, Thrombocytopenia.

Related